ePrints@IIScePrints@IISc Home | About | Browse | Latest Additions | Advanced Search | Contact | Help

Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation I as augmentation therapeutic strategy approaches in muscular dystrophy

Afzal, Ehsan and Zakeri, Saba and Keyhanvar, Peyman and Bagheri, Meisam and Mahjoubi, Parvin and Asadian, Mahtab and Omoomi, Nogol and Dehqanian, Mohammad and Ghalandarlaki, Negar and Darvishmohammadi, Tahmineh and Farjadian, Fatemeh and Golvajoee, Mohammad Sadegh and Afzal, Shadi and Ghaffari, Maryam and Cohan, Reza Ahangari and Gravand, Amin and Ardestani, Mehdi Shafiee (2013) Nanolipodendrosome-loaded glatiramer acetate and myogenic differentiation I as augmentation therapeutic strategy approaches in muscular dystrophy. In: INTERNATIONAL JOURNAL OF NANOMEDICINE, 8 . pp. 2943-2960.

[img] PDF
int_jou_nan_2013.pdf - Published Version
Restricted to Registered users only

Download (2MB) | Request a copy
Official URL: http://dx.doi.org/10.2147/IJN.S43219

Abstract

Backgrond: Muscular dystrophies consist of a number of juvenile and adult forms of complex disorders which generally cause weakness or efficiency defects affecting skeletal muscles or, in some kinds, other types of tissues in all parts of the body are vastly affected. In previous studies, it was observed that along with muscular dystrophy, immune inflammation was caused by inflammatory cells invasion - like T lymphocyte markers (CD8+/CD4+). Inflammatory processes play a major part in muscular fibrosis in muscular dystrophy patients. Additionally, a significant decrease in amounts of two myogenic recovery factors (myogenic differentation 1 MyoD] and myogenin) in animal models was observed. The drug glatiramer acetate causes anti-inflammatory cytokines to increase and T helper (Th) cells to induce, in an as yet unknown mechanism. MyoD recovery activity in muscular cells justifies using it alongside this drug. Methods: In this study, a nanolipodendrosome carrier as a drug delivery system was designed. The purpose of the system was to maximize the delivery and efficiency of the two drug factors, MyoD and myogenin, and introduce them as novel therapeutic agents in muscular dystrophy phenotypic mice. The generation of new muscular cells was analyzed in SW1 mice. Then, immune system changes and probable side effects after injecting the nanodrug formulations were investigated. Results: The loaded lipodendrimer nanocarrier with the candidate drug, in comparison with the nandrolone control drug, caused a significant increase in muscular mass, a reduction in CD4+/CD8+ inflammation markers, and no significant toxicity was observed. The results support the hypothesis that the nanolipodendrimer containing the two candidate drugs will probably be an efficient means to ameliorate muscular degeneration, and warrants further investigation.

Item Type: Journal Article
Additional Information: Copyright of this article is belongs to DOVE MEDICAL PRESS LTD
Keywords: muscular dystrophy; glatiramer acetate; MyoD factor; drug delivery
Department/Centre: Division of Biological Sciences > Molecular Reproduction, Development & Genetics
Depositing User: Id for Latest eprints
Date Deposited: 27 Sep 2013 08:00
Last Modified: 27 Sep 2013 08:00
URI: http://eprints.iisc.ac.in/id/eprint/47331

Actions (login required)

View Item View Item